Servier shared on LinkedIn:
“ESMO26 is now over! We were pleased to share the latest in oncology science and up‑to‑date education with the global oncology community.
In line with our Servier 2030 ambition, we invest close to 70% of our R/D budget in oncology. Our research is focused on rare cancers to address high unmet medical needs among patients.
Learn more about our commitment to oncology.”
Other articles about ESMO 2026 on OncoDaily.
